Skip to main content
Journal cover image

448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study

Publication ,  Conference
Stadtmauer, E; Karlin, L; Weisel, K; Gatt, ME; Kansagra, A; Monohan, G; Yee, A; Rockow-Magnone, S; Cordero, J; Hoffman, D; Bueno, O; Wu, K ...
Published in: Journal for ImmunoTherapy of Cancer
November 2021

Duke Scholars

Published In

Journal for ImmunoTherapy of Cancer

DOI

EISSN

2051-1426

Publication Date

November 2021

Volume

9

Issue

Suppl 2

Start / End Page

A476 / A476

Publisher

BMJ
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stadtmauer, E., Karlin, L., Weisel, K., Gatt, M. E., Kansagra, A., Monohan, G., … Gasparetto, C. (2021). 448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. In Journal for ImmunoTherapy of Cancer (Vol. 9, pp. A476–A476). BMJ. https://doi.org/10.1136/jitc-2021-sitc2021.448
Stadtmauer, Edward, Lionel Karlin, Katja Weisel, Moshe Etzion Gatt, Ankit Kansagra, Gregory Monohan, Andrew Yee, et al. “448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study.” In Journal for ImmunoTherapy of Cancer, 9:A476–A476. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.448.
Stadtmauer E, Karlin L, Weisel K, Gatt ME, Kansagra A, Monohan G, et al. 448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. In: Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A476–A476.
Stadtmauer, Edward, et al. “448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, BMJ, 2021, pp. A476–A476. Crossref, doi:10.1136/jitc-2021-sitc2021.448.
Stadtmauer E, Karlin L, Weisel K, Gatt ME, Kansagra A, Monohan G, Yee A, Rockow-Magnone S, Cordero J, Hoffman D, Bueno O, Wu K, Gasparetto C. 448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A476–A476.
Journal cover image

Published In

Journal for ImmunoTherapy of Cancer

DOI

EISSN

2051-1426

Publication Date

November 2021

Volume

9

Issue

Suppl 2

Start / End Page

A476 / A476

Publisher

BMJ